Skip to main content
hello world

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates

PR Newswire - Tue Aug 8, 2023

First patient dosed in second cohort of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 

Read more at prnewswire.com